The drug combination is recommended for usage in adult patients with HR+ and HER2- breast cancer. Credit: NICE.

The UK National Institute for Health and Care Excellence (Nice) has granted approval for Pfizer’s palbociclib (Ibrance) in combination with anti-cancer therapy, fulvestrant, to treat advanced breast cancer patients. 

With the publication of the final draft guidance by the institute, the combination therapy will be offered for routine use in the National Health Service (NHS).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The ‘life-extending’ drug combination is recommended for usage in adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer who have previously received hormone therapy.

Since 2020, palbociclib has been offered through the Cancer Drugs Fund (CDF), while additional data was obtained to address doubts on the drug’s cost efficiency and to what extent it prolongs the life expectancy of people.

An inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6), palbociclib is administered once a day as a pill.

It acts by hindering proteins in cancer cells to avert cell division and growth.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NICE medicines evaluation interim director Helen Knight said: “The decision is fantastic news for up to 2,400 people with advanced breast cancer who have already had endocrine treatment. 

“It provides a further valuable treatment option that can increase the time they remain in good health and delay the need for chemotherapy and its associated side effects.

“As our evaluation of palbociclib shows, this process works well when companies engage with NICE and NHS England to price their medicines reasonably and present a clear case for additional evidence to be gathered while they’re in the CDF.”

In addition to palbociclib, NICE has granted approval for 15 other therapies for breast cancer since 2018.

In July, the institute recommended Novartis Pharmaceuticals UK’s Piqray (alpelisib) plus fulvestrant to treat HR+, HER2- and PIK3CA-mutated locally advanced or metastatic breast cancer.